Sirona Biochem Corp V.SBM

Alternate Symbol(s): SRBCF

Healthcare Biotechnology

Sirona Biochem Corp. is a cosmetic ingredient and drug discovery company with a proprietary technology platform developed at its laboratory facility in France with a specialization in the stabilization of carbohydrate molecules. The Company is exploring the areas of diabetes, dyschromia, anti-aging, anti-cellulite and antiviral therapies and relies on a business model of licensing patents to large organizations in return for up-front and milestone payments as well as royalties. Its two most advanced programs are the cosmetic skin lightener and diabetes drug. The Company's TFC-1067 is for the treatment of Dyschromia (Dark spots on the skin). GlycoProteMim is a novel anti-aging compound. GlycoProteMim is based on the naturally occurring glycoproteins found in Antarctic fish, known to protect them against environmental stressors. It is focused on three current antiviral categories: Neuraminidase Inhibitors, Nucleoside Analogs and Iminosugars. Its wholly owned subsidiary is TFChem S.A.R.L.

TSXV:SBM - Post by User

Sirona Biochem Corp > TFC-1067 and SGLT2

<< Previous

Bullboard Posts

Next >>

Comment by lscfaon Jan 07, 2021 2:38pm

206 Views

Post# 32245359

RE:RE:TFC-1067 and SGLT2

p.s. the co. had these trial results in April 2019 but kept using the term skin lightener in news releases until June 2020. Misleading or what?

lscfa wrote: Co. stopped using skin lightening descriptor because of trial results....

TFC1067 and 2% hydroquinone produced statistically significant skin lightening after 8 weeks of use, but only hydroquinone lightened the normal skin.

https://onlinelibrary.wiley.com/doi/10.1111/jocd.13771

forhandlaren wrote: I recall that Howard stated R+F product release 15-18 months after the signed deal, check out video interview during summer '19.

That would translate to Q1'21. Considering the ongoing compound production at two different sites it would be possible. Let's hope for the best.

I agree that the company quietly has changed the TFC-1067 from Skin Lightener in the broad sense to a more narrow dark spot lightener. Not sure why.

Seems like the same compound, otherwise I would bet on multiple compounds with different properties/effects.

If different I'd say they just follow the changed sentiment on the market. Don't think it is as politically correct as before to market lighter skin.

I'm actually not very happy about the lightening in order to strive for this cultural ideal, but when bad and dangerous treatments could be replaced with a safe one - and the market would persist anyway - I'm all for it.

The next news seems to be SGLT2 for pets. Does anyone know how the difference in scientific steps/requirements between human och pet meds?